Short Interest in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Drops By 46.8%

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the target of a large decrease in short interest in the month of August. As of August 31st, there was short interest totaling 199,260 shares, a decrease of 46.8% from the August 15th total of 374,802 shares. Approximately 1.8% of the shares of the company are sold short. Based on an average trading volume of 109,753 shares, the short-interest ratio is presently 1.8 days.

Hong Kong Pharma Digital Technology Price Performance

HKPD stock traded up $0.00 during trading on Thursday, reaching $0.12. The stock had a trading volume of 1,272,336 shares, compared to its average volume of 1,448,428. The company has a quick ratio of 3.75, a current ratio of 3.86 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average is $0.34 and its two-hundred day moving average is $0.48. Hong Kong Pharma Digital Technology has a 52 week low of $0.10 and a 52 week high of $1.82.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.04) earnings per share (EPS) for the quarter. The business had revenue of $3.15 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Hong Kong Pharma Digital Technology from a “sell (d)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.